Thomas O Carpenter

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/7816953/thomas-o-carpenter-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

86
papers
4,561
citations
4,561
h-index

95
ext. papers

5,518
ext. citations

8.5
avg, IF

L-index

#	Paper	IF	Citations
86	Sustained efficacy and safety of burosumab, a monoclonal antibody to FGF23, in children with X-linked hypophosphatemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 ,	5.6	6
85	Case 32-2021: A 14-Year-Old Girl with Swelling of the Jaw and Hypercalcemia. <i>New England Journal of Medicine</i> , 2021 , 385, 1604-1613	59.2	2
84	Serum Levels of Lipocalin Are Lower in Adolescents With X-Linked Hypophosphatemia. <i>Journal of the Endocrine Society</i> , 2021 , 5, A27-A27	0.4	1
83	Reply to: Burosumab for Tumor-Induced Osteomalacia: not Enough of a Good Thing. <i>Journal of Bone and Mineral Research</i> , 2021 ,	6.3	1
82	Burosumab for the Treatment of Tumor-Induced Osteomalacia. <i>Journal of Bone and Mineral Research</i> , 2021 , 36, 627-635	6.3	29
81	Different elemental infant formulas show equivalent phosphorus and calcium bioavailability in healthy volunteers. <i>Nutrition Research</i> , 2021 , 85, 71-83	4	2
80	Response of the ENPP1-Deficient Skeletal Phenotype to Oral Phosphate Supplementation and/or Enzyme Replacement Therapy: Comparative Studies in Humans and Mice. <i>Journal of Bone and Mineral Research</i> , 2021 , 36, 942-955	6.3	2
79	Novel homozygous variant in BMP1 associated with a rare osteogenesis imperfecta phenotype. <i>Osteoporosis International</i> , 2021 , 32, 1239-1244	5.3	1
78	25-OHD response to vitamin D supplementation in children: effect of dose but not GC haplotype. <i>European Journal of Endocrinology</i> , 2021 , 185, 333-342	6.5	O
77	Phosphorus bioaccessibility measured in four amino acid-based formulas using in-vitro batch digestion translates well into phosphorus bioavailability in mice. <i>Nutrition</i> , 2021 , 89, 111291	4.8	
76	Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 323, 432-443	27.4	73
75	SUN-LB19 Novel Homozygous Mutation in BMP1 Causing Osteogenesis Imperfecta. <i>Journal of the Endocrine Society</i> , 2020 , 4,	0.4	78
74	Human Heterozygous ENPP1 Deficiency Is Associated With Early Onset Osteoporosis, a Phenotype Recapitulated in a Mouse Model of Enpp1 Deficiency. <i>Journal of Bone and Mineral Research</i> , 2020 , 35, 528-539	6.3	18
73	Phosphorus homeostasis and related disorders 2020 , 469-507		1
7 ²	Frequent overexpression of klotho in fusion-negative phosphaturic mesenchymal tumors with tumorigenic implications. <i>Modern Pathology</i> , 2020 , 33, 858-870	9.8	7
71	Relationship of Total and Free 25-Hydroxyvitamin D to Biomarkers and Metabolic Indices in Healthy Children. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	5
70	Long-Term Follow-up of Hypophosphatemic Bone Disease Associated With Elemental Formula Use: Sustained Correction of Bone Disease After Formula Change or Phosphate Supplementation. <i>Clinical Pediatrics</i> , 2020 , 59, 1080-1085	1.2	3

(2016-2020)

69	Growth Curves for Children with X-linked Hypophosphatemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	11
68	Severity of reduced bone mineral density and risk of fractures in long-term survivors of childhood leukemia and lymphoma undergoing guideline-recommended surveillance for bone health. <i>Cancer</i> , 2020 , 126, 202-210	6.4	6
67	High dose vitamin D supplementation does not rescue bone loss following Roux-en-Y gastric bypass in female rats. <i>Bone</i> , 2019 , 127, 172-180	4.7	6
66	Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period. <i>Calcified Tissue International</i> , 2019 , 105, 271-284	3.9	47
65	Rickets severity predicts clinical outcomes in children with X-linked hypophosphatemia: Utility of the radiographic Rickets Severity Score. <i>Bone</i> , 2019 , 122, 76-81	4.7	28
64	Description of 5 Novel NPT2c Mutations Causing Hereditary Hypophosphatemic Rickets With Hypercalciuria. <i>Kidney International Reports</i> , 2019 , 4, 1179-1186	4.1	8
63	Efficacy and safety of burosumab in children aged 1-4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial. <i>Lancet Diabetes and Endocrinology,the</i> , 2019 , 7, 189-199	18.1	69
62	Skeletal disease in a father and daughter with a novel monoallelic WNT1 mutation. <i>Bone Reports</i> , 2018 , 9, 154-158	2.6	1
61	Disorders of Mineral Metabolism in Childhood 2018 , 705-712		
60	Burosumab Therapy in Children with X-Linked Hypophosphatemia. <i>New England Journal of Medicine</i> , 2018 , 378, 1987-1998	59.2	214
59	Rickets: The Skeletal Disorders of Impaired Calcium or Phosphate Availability 2018 , 497-524		2
58	A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of		
	Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis. <i>Journal of Bone and Mineral Research</i> , 2018 , 33, 1383-1393	6.3	134
57	Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis. <i>Journal of Bone and Mineral Research</i> , 2018 , 33, 1383-1393 Unexpected widespread hypophosphatemia and bone disease associated with elemental formula	6.3 4.7	37
57 56	Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis. <i>Journal of Bone and Mineral Research</i> , 2018 , 33, 1383-1393 Unexpected widespread hypophosphatemia and bone disease associated with elemental formula use in infants and children. <i>Bone</i> , 2017 , 97, 287-292 CYP24A1 loss of function: Clinical phenotype of monoallelic and biallelic mutations. <i>Journal of</i>		
	Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis. <i>Journal of Bone and Mineral Research</i> , 2018 , 33, 1383-1393 Unexpected widespread hypophosphatemia and bone disease associated with elemental formula use in infants and children. <i>Bone</i> , 2017 , 97, 287-292 CYP24A1 loss of function: Clinical phenotype of monoallelic and biallelic mutations. <i>Journal of</i>	4.7	37
56	Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis. <i>Journal of Bone and Mineral Research</i> , 2018 , 33, 1383-1393 Unexpected widespread hypophosphatemia and bone disease associated with elemental formula use in infants and children. <i>Bone</i> , 2017 , 97, 287-292 CYP24A1 loss of function: Clinical phenotype of monoallelic and biallelic mutations. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2017 , 173, 337-340 Rickets. <i>Nature Reviews Disease Primers</i> , 2017 , 3, 17101	4·7 5·1	37
56 55	Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis. <i>Journal of Bone and Mineral Research</i> , 2018 , 33, 1383-1393 Unexpected widespread hypophosphatemia and bone disease associated with elemental formula use in infants and children. <i>Bone</i> , 2017 , 97, 287-292 CYP24A1 loss of function: Clinical phenotype of monoallelic and biallelic mutations. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2017 , 173, 337-340 Rickets. <i>Nature Reviews Disease Primers</i> , 2017 , 3, 17101 Characterization of FN1-FGFR1 and novel FN1-FGF1 fusion genes in a large series of phosphaturic	4·7 5·1 51.1	37 36 85

51	Characterization of additional vitamin D binding protein variants. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2016 , 159, 54-9	5.1	3
50	Population pharmacokinetic and pharmacodynamic analyses from a 4-month intradose escalation and its subsequent 12-month dose titration studies for a human monoclonal anti-FGF23 antibody (KRN23) in adults with X-linked hypophosphatemia. <i>Journal of Clinical Pharmacology</i> , 2016 , 56, 429-38	2.9	14
49	Pigment epithelium-derived factor restoration increases bone mass and improves bone plasticity in a model of osteogenesis imperfecta type VI via Wnt3a blockade. <i>FASEB Journal</i> , 2016 , 30, 2837-48	0.9	24
48	Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia. <i>Bone Reports</i> , 2016 , 5, 158-162	2.6	40
47	Pharmacokinetics and pharmacodynamics of a human monoclonal anti-FGF23 antibody (KRN23) in the first multiple ascending-dose trial treating adults with X-linked hypophosphatemia. <i>Journal of Clinical Pharmacology</i> , 2016 , 56, 176-85	2.9	29
46	Hypophosphatemic rickets: lessons from disrupted FGF23 control of phosphorus homeostasis. Current Osteoporosis Reports, 2015 , 13, 88-97	5.4	40
45	Prolonged Correction of Serum Phosphorus in Adults With X-Linked Hypophosphatemia Using Monthly Doses of KRN23. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 2565-73	5.6	106
44	A Practical Clinical Approach to Paediatric Phosphate Disorders. <i>Endocrine Development</i> , 2015 , 28, 134-	161	10
43	Contemporary Medical and Surgical Management of X-linked Hypophosphatemic Rickets. <i>Journal of the American Academy of Orthopaedic Surgeons, The</i> , 2015 , 23, 433-42	4.5	21
42	Association between serum 25-hydroxyvitamin D level and pulmonary exacerbations in cystic fibrosis. <i>Pediatric Pulmonology</i> , 2015 , 50, 441-6	3.5	26
41	Conventional Therapy in Adults With X-Linked Hypophosphatemia: Effects on Enthesopathy and Dental Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 3625-32	5.6	69
40	Mutations in SLC34A3/NPT2c are associated with kidney stones and nephrocalcinosis. <i>Journal of the American Society of Nephrology: JASN</i> , 2014 , 25, 2366-75	12.7	99
39	Gastric bypass in obese rats causes bone loss, vitamin D deficiency, metabolic acidosis, and elevated peptide YY. <i>Surgery for Obesity and Related Diseases</i> , 2014 , 10, 878-84	3	22
38	Effect of vitamin D-binding protein genotype on the development of asthma in children. <i>Annals of Allergy, Asthma and Immunology</i> , 2014 , 112, 519-24	3.2	23
37	Effect of paricalcitol on circulating parathyroid hormone in X-linked hypophosphatemia: a randomized, double-blind, placebo-controlled study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, 3103-11	5.6	20
36	Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. <i>Journal of Clinical Investigation</i> , 2014 , 124, 1587-97	15.9	211
35	Exome sequencing reveals FAM20c mutations associated with fibroblast growth factor 23-related hypophosphatemia, dental anomalies, and ectopic calcification. <i>Journal of Bone and Mineral Research</i> , 2013 , 28, 1378-85	6.3	125
34	Vitamin D binding protein is a key determinant of 25-hydroxyvitamin D levels in infants and toddlers. <i>Journal of Bone and Mineral Research</i> , 2013 , 28, 213-21	6.3	75

33	Rickets: The Skeletal Disorders of Impaired Calcium or Phosphate Availability 2013 , 357-378		1
32	Heart failure in hypophosphatemic rickets: complications from high-dose phosphate therapy. <i>Endocrine Practice</i> , 2013 , 19, e8-e11	3.2	6
31	The expanding family of hypophosphatemic syndromes. <i>Journal of Bone and Mineral Metabolism</i> , 2012 , 30, 1-9	2.9	119
30	Familial Hypophosphatemia and Related Disorders 2012 , 699-726		4
29	Genetic defect in CYP24A1, the vitamin D 24-hydroxylase gene, in a patient with severe infantile hypercalcemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, E268-74	5.6	90
28	Demographic, dietary, and biochemical determinants of vitamin D status in inner-city children. <i>American Journal of Clinical Nutrition</i> , 2012 , 95, 137-46	7	49
27	Calcitonin administration in X-linked hypophosphatemia. <i>New England Journal of Medicine</i> , 2011 , 364, 1678-80	59.2	32
26	A clinicianঙ guide to X-linked hypophosphatemia. <i>Journal of Bone and Mineral Research</i> , 2011 , 26, 1381-	-8 6.3	332
25	Nuclear isoforms of fibroblast growth factor 2 are novel inducers of hypophosphatemia via modulation of FGF23 and KLOTHO. <i>Journal of Biological Chemistry</i> , 2010 , 285, 2834-46	5.4	49
24	Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010 , 95, 1846-50	5.6	118
23	Circulating levels of soluble klotho and FGF23 in X-linked hypophosphatemia: circadian variance, effects of treatment, and relationship to parathyroid status. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010 , 95, E352-7	5.6	104
22	Variations in cord 25-hydroxyvitamin D levels in Hispanic and Caucasian infants are not related to neonatal bone mineral status. <i>FASEB Journal</i> , 2010 , 24, 325.4	0.9	
21	Survey of the enthesopathy of X-linked hypophosphatemia and its characterization in Hyp mice. <i>Calcified Tissue International</i> , 2009 , 85, 235-46	3.9	73
20	A translocation causing increased alpha-klotho level results in hypophosphatemic rickets and hyperparathyroidism. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 3455-60	11.5	188
19	A novel missense mutation in SLC34A3 that causes hereditary hypophosphatemic rickets with hypercalciuria in humans identifies threonine 137 as an important determinant of sodium-phosphate cotransport in NaPi-IIc. <i>American Journal of Physiology - Renal Physiology</i> , 2008 ,	4.3	64
18	295, F371-9 Evaluation of bone and mineral disorders. <i>Pediatric Endocrinology Reviews</i> , 2007 , 5 Suppl 1, 584-98	1.1	14
17	A randomized controlled study of effects of dietary magnesium oxide supplementation on bone mineral content in healthy girls. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006 , 91, 4866-72	5.6	56
16	SLC34A3 mutations in patients with hereditary hypophosphatemic rickets with hypercalciuria predict a key role for the sodium-phosphate cotransporter NaPi-IIc in maintaining phosphate homeostasis. <i>American Journal of Human Genetics</i> , 2006 , 78, 179-92	11	370

15	Surveillance for early detection of aggressive parathyroid disease: carcinoma and atypical adenoma in familial isolated hyperparathyroidism associated with a germline HRPT2 mutation. <i>Journal of Bone and Mineral Research</i> , 2006 , 21, 1666-71	6.3	58	
14	Relationships among vitamin D levels, parathyroid hormone, and calcium absorption in young adolescents. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 5576-81	5.6	139	
13	Fibroblast growth factor 7: an inhibitor of phosphate transport derived from oncogenic osteomalacia-causing tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 1012-20	5.6	125	
12	Nutritional rickets with normal circulating 25-hydroxyvitamin D: a call for reexamining the role of dietary calcium intake in North American infants. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 3539-45	5.6	121	
11	Familial Hypophosphatemia and Related Disorders 2003, 603-XVI		9	
10	Hereditary hypophosphatemic rickets with hypercalciuria is not caused by mutations in the Na/Pi cotransporter NPT2 gene. <i>Journal of the American Society of Nephrology: JASN</i> , 2001 , 12, 507-514	12.7	57	
9	Changes in bone turnover in young women consuming different levels of dietary protein. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999 , 84, 1052-5	5.6	83	
8	Osteocalcin production in primary osteoblast cultures derived from normal and Hyp mice. <i>Endocrinology</i> , 1998 , 139, 35-43	4.8	49	
7	New perspectives on the biology and treatment of X-linked hypophosphatemic rickets. <i>Pediatric Clinics of North America</i> , 1997 , 44, 443-66	3.6	75	
6	Sonography of congenital adrenal hyperplasia due to partial deficiency of 3beta-hydroxysteroid dehydrogenase: a case report. <i>Pediatric Radiology</i> , 1997 , 27, 594-5	2.8	7	
5	Media calcium attenuates mitochondrial 1,25(OH)2D production in phosphorus or vitamin D-deprived rats. <i>Pediatric Research</i> , 1995 , 37, 726-30	3.2	8	
4	Secretion of a large molecular-weight form of insulin-like growth factor by a primary renal tumor. <i>Medical and Pediatric Oncology</i> , 1995 , 24, 392-6		7	
3	Vitamin D metabolism in chronic childhood hypoparathyroidism: evidence for a direct regulatory effect of calcium. <i>Journal of Pediatrics</i> , 1990 , 116, 252-7	3.6	8	
2	Mutational Analysis and Genotype-Phenotype Correlation of the PHEX Gene in X-Linked Hypophosphatemic Rickets		22	
1	Disorders of Mineral Metabolism in Childhood651-658		1	